首页 | 本学科首页   官方微博 | 高级检索  
检索        

乌司他丁对脓毒性休克病人肺毛细血管通透性和复苏效果的影响
引用本文:周帆,黄云峰,王光林.乌司他丁对脓毒性休克病人肺毛细血管通透性和复苏效果的影响[J].安徽医药,2019,23(6):1234-1236.
作者姓名:周帆  黄云峰  王光林
作者单位:黄冈市中心医院急诊科,湖北 黄冈,438000;黄冈市中心医院急诊科,湖北 黄冈,438000;黄冈市中心医院急诊科,湖北 黄冈,438000
摘    要:目的研究乌司他丁对脓毒性休克病人肺毛细血管通透性和复苏效果的影响,为临床诊疗提供依据。方法 收集2014年3月到2017年3月黄冈市中心医院收治的脓毒性休克病人70例的临床资料,根据是否应用乌司他丁将病人分为研究组(n=36例)和对照组(n=34例),比较两组血管外肺水指数(PVPI)、肺血管通透性指数(EVLWI)、心输出量(CI)、中心静脉压(CVP)、外周血管阻力指数(SVRI)、氧合作用、乳酸、晶体液体总量、胶体液体总量、清蛋白及血管活性药物使用评分情况。结果 经过治疗后;对照组的PVPI从(0.63±0.03)降低为(0.52±0.02),研究组的PVPI从(0.62±0.03)降低为(0.43±0.04);对照组的EVLWI从(12.02±3.54)mL/kg升高为(18.93±3.17)mL/kg,研究组的PVPI从(11.74±2.31)mL/kg降低为(9.43±1.09)mL/kg,研究组PVPI、EVLWI改善优于对照组(t=11.797,16.957,均P=0.000),研究组胶体液体总量和清蛋白用量低于对照组(1 556.71±12.10)mL 比(794.20±11.31)mL,(67.61±3.81)g/L 比(30.51±5.82)g/L],差异有统计学意义(t=272.521,31.356,均P=0.000),经过治疗后,对照组的氧合作用从(1.02±0.04)升高为(1.35±0.19),研究组的氧合作用从(1.01±0.02)降低为(0.53±0.02),对照组的乳酸从(7.48±1.13)mmol/L降低为(3.65±1.23)mmol/L,研究组的PVPI从(7.89±1.42)mmol/L降低为(2.43±1.04)mmol/L,研究组氧合作用、乳酸改善优于对照组(t=25.755,4.490,均P=0.000)。结论 乌司他丁治疗脓毒性休克病人效果较好,能改善肺毛细血管通透性,降低复苏所需胶体液体和清蛋白总量,提高复苏效果。

关 键 词:乌司他丁  脓毒性休克  肺毛细血管
收稿时间:2017/5/26 0:00:00
修稿时间:2017/7/11 0:00:00

Effects of Ulinastatin on pulmonary capillary permeability and resuscitation in patients with septic shock
ZHOU Fan,HUANG Yunfeng and WANG Guanglin.Effects of Ulinastatin on pulmonary capillary permeability and resuscitation in patients with septic shock[J].Anhui Medical and Pharmaceutical Journal,2019,23(6):1234-1236.
Authors:ZHOU Fan  HUANG Yunfeng and WANG Guanglin
Institution:Emergency Department,Huanggang Central Hospital,Huanggang,Hubei 438000,China,Emergency Department,Huanggang Central Hospital,Huanggang,Hubei 438000,China and Emergency Department,Huanggang Central Hospital,Huanggang,Hubei 438000,China
Abstract:Objective To study the effects of Ulinastatin on pulmonary capillary permeability and resuscitation in patients with septic shock,and to provide the basis for clinical diagnosis and treatment.Methods Clinical data of 70 patients with septic shock admitted to Huanggang Central Hospital from March 2014 to March 2017 were collected.The patients were assigned into study group (n=36) and control group (n=34) according to whether Ulinastatin was used or not.The extravascular lung water index (EVLWI),pulmonary vascular permeability index (PVPI),cardiac output (CI),central venous pressure (CVP),systemic vascular resistance index (SVRI),oxygenation,lactic acid,total amount of liquid crystal and colloid fluid volume,albumin and vascular active drug use score of two groups were compared.Results After treatment,the PVPI of the control group decreased from (0.63±0.03) to (0.52±0.02),and the PVPI of the study group decreased from (0.62±0.03) to (0.43±0.04).The EVLWI of the control group increased from (12.02±3.54) mL/kg to (18.93±3.17) mL/kg,and the EVLWI of the study group decreased from (11.74±2.31) mL/kg to (9.43±1.09) mL/kg.The improvement of PVPI and EVLWI in the study group was better than that in the control group (t=11.797,6.957,all P=0.000).The total amount of colloidal fluid and albumin in the study group were lower than those in the control group (1 556.71±12.10) mL vs. (794.20±11.31) mL,(67.61±3.81) g/L vs. (30.51±5.82) g/L],and the difference was statistically significant (t=272.521,1.356,all P=0.000).After treatment,the oxygenation of the control group increased from (1.02±0.04) to (1.35±0.19),and the oxygenation of the study group decreased from (1.01±0.02) to (0.53±0.02).The lactic acid of the control group decreased from (7.48±1.13) mmol/L to (3.65±1.23) mmol/L,and the PVPI of the study group decreased from (7.89±1.42) mmol/L to (2.43±1.04) mmol/L.The oxygenation and lactic acid improvement of the study group were better than the control group (t=25.755,4.490,all P=0.000).Conclusion Ulinastatin in treatment of septic shock has better results.It can improve the pulmonary capillary permeability,reduce the total amount of colloidal liquid and albumin,and improve the recovery effect.
Keywords:Ulinastatin  Septic shock  Pulmonary capillary
本文献已被 万方数据 等数据库收录!
点击此处可从《安徽医药》浏览原始摘要信息
点击此处可从《安徽医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号